Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Despite the proven efficacy of Sativex(®) (9-delta-tetrahydrocannabinol plus cannabidiol) oromucosal spray in reducing spasticity symptoms in multiple sclerosis (MS), little is known about the neurophysiological correlates of such effects. The aim of the study was to investigate the effects of Sativex on neurophysiological measures of spasticity (H/M ratio) and corticospinal excitability in patients with progressive MS. This was a randomized, double-blind, placebo-controlled, crossover study. Consecutive subjects with progressive MS and lower limb spasticity referred to our center were randomized to 4 weeks' treatment (including 2 weeks' titration) with Sativex or placebo, with crossover after a 2-week washout. Clinical and neurophysiological measures (H/M ratio and cortical excitability) of spasticity were assessed. The H/M ratio was the primary outcome, with sample size calculation of 40 patients. Of 44 recruited patients, 34 were analyzed due to 6 drop-outs and 4 exclusions, which lowered the power of the study to show differences between treatments. Neurophysiological measures did not differ significantly according to treatment and did not correlate significantly with clinical response. Response on the modified Ashworth scale (at least 20 % improvement) was significantly more frequent after Sativex than placebo (50 vs 23.5 %; p = 0.041; McNemar). Side effects did not differ significantly according to treatment. Our findings confirm the clinical benefit of Sativex on MS sp…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,424
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Rossini, P. M., Barker, A. T., Berardelli, A., Caramia, M. D., Caruso, G., Cracco, R. Q., Dimitrijević, M. R., Hallett, M., Katayama, Y., Lücking, C. H., et al. (1994) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(94)90029-9 · Cited by 3,030
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Development of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. R. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,190
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Cannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Research works printed but not linked: 1
- Rymer WZ, Katz RT (1994) Mechanisms of spastic hypertonia. Phys Med Rehabil State Art Rev 8:441–454
Cited by
Abrams, D. I. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.003 · Cited by 296
Fisher, E., Moore, R. A., Fogarty, A. E., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., Krane, E., Rice, A. S. C., Rowbotham, M., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000001929 · Cited by 215
“4 Leocani et al.(37) 38 2 Nabiximols Placebo 4 Markova, 2019(40) 96 2 Nabiximols Placebo 4 Zajicek et al.”
BackgroundResultBilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“…would be finding the genetically regulated CB1 function in order to predict clinical response to cannabinoid treatment of spasticity (Coghe et al., 2015; Leocani et al., 2015), and to improve patient stratification as a tool for personalized rehabilitation of MS patients with disability.”
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
Patti, F., Messina, S., Solaro, C. M., Amato, M. P., Bergamaschi, R., Bonavita, S., Bossio, R. B., Morra, V. B., Costantino, G., Cavalla, P., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312591 · Cited by 123
Self-citation
Metadata
- Authors
- Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del Carro, U., Amadio, S., Straffi, L., Rossi, P., Martinelli, V., Vila, C., Sormani, M. P., & Comi, G.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- IRCCS Ospedale San Raffaele (IT)
- University of Genoa (IT)
- Almirall (Spain) (ES)
- Corresponding author
- Leocani, Letizia
- ORCID
- Venue
- Journal of Neurology
- Published
- 2015-08-20
- Volume
- 262
- Issue
- 11
- Pages
- 2520-2527
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W1181448258
- Cited by
- 66
- References
- 40
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 11 · 2021: 5 · 2020: 12 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 5 · 2015: 1
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- Sativex, multiple sclerosis, progressive multiple sclerosis, spasticity, corticospinal excitability, H/M ratio, lower limb spasticity, Modified Ashworth Scale, cannabinoids
- MeSH terms
- Adult, Cannabidiol, Cerebral Cortex, Double-Blind Method, Drug Combinations, Electric Stimulation, Electromyography, Female, Humans, Male, Middle Aged, Muscle Spasticity, Plant Extracts, Severity of Illness Index, Dronabinol, Outcome Assessment, Health Care, Cross-Over Studies, Evoked Potentials, Motor, Multiple Sclerosis, Chronic Progressive, Transcranial Magnetic Stimulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis. https://app.cochat.ai/papers/10.1007/s00415-015-7878-1
- The paper
- Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del Carro, U., Amadio, S., Straffi, L., Rossi, P., Martinelli, V., Vila, C., Sormani, M. P., & Comi, G. (2015). Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis. Journal of Neurology. https://doi.org/10.1007/s00415-015-7878-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.